| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $341K | — | +44.3% |
| SG&A Expense | $355K | — | -19.0% |
| Operating Income | -$696K | — | -3.1% |
| Net Income | -$686K | — | -8.5% |
| EPS (Basic) | $0.00 | — | — |
| EPS (Diluted) | $0.00 | — | — |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.3M | -45.7% | -70.1% |
| Current Assets | $1.4M | -43.8% | -68.9% |
| Total Assets | $1.4M | -42.9% | -68.2% |
| Current Liabilities | $382K | -50.1% | +303.7% |
| Long-term Debt | $29K | -20.4% | -49.7% |
| Total Liabilities | $3.4M | -10.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.1M | — | +15.6% |
| +8.2% |
| Stockholders' Equity | -$2.0M | -53.1% | -246.3% |